Danpure H J, Osman S
Br J Radiol. 1986 Sep;59(705):907-10. doi: 10.1259/0007-1285-59-705-907.
When blood cells are radiolabelled in plasma, for example with 111In-tropolonate, the plasma always contains an anticoagulant, usually acid-citrate-dextrose (ACD) or heparin. The effect of ACD and heparin on the labelling efficiency (LE) and optimum concentration of ligand required to radiolabel human granulocytes in plasma with 111In-tropolonate or 111In-2-mercaptopyridine-N-oxide (111In-merc) has been measured. The concentrations of ligand (tropolone or merc) required for maximum cell labelling in plasma containing ACD were 4 X 10(-4) M tropolone and 1 X 10(-4) M merc, whereas using plasma containing heparin, the optimum concentrations were 10-fold higher, at 4 X 10(-3) M and 1 X 10(-3) M respectively. At the optimum ligand concentrations, the LE for 1 X 10(8) granulocytes labelled in plasma containing ACD was 90% using 111In-tropolonate and 82% using 111In-merc, whereas using plasma containing heparin they were 68% and only 20%, respectively. Addition of ACD to heparinised plasma abolished the necessity for more ligand and increased the LE to the same values as those for plasma containing ACD alone. These results clearly demonstrate that to obtain a high LE using the lowest possible concentrations of tropolone or merc, the granulocytes must be labelled in plasma containing ACD.
当血细胞在血浆中进行放射性标记时，例如用铟-111 托品酸盐，血浆中总是含有抗凝剂，通常是酸性枸橼酸盐葡萄糖（ACD）或肝素。已经测定了 ACD 和肝素对用铟-111 托品酸盐或铟-111 2-巯基吡啶-N-氧化物（铟-111 巯基）在血浆中对人粒细胞进行放射性标记的标记效率（LE）和所需配体最佳浓度的影响。在含有 ACD 的血浆中实现最大细胞标记所需的配体（托品酮或巯基）浓度分别为 4×10⁻⁴ M 托品酮和 1×10⁻⁴ M 巯基，而使用含有肝素的血浆时，最佳浓度高出 10 倍，分别为 4×10⁻³ M 和 1×10⁻³ M。在最佳配体浓度下，用铟-111 托品酸盐在含有 ACD 的血浆中标记 1×10⁸ 个粒细胞时的 LE 为 90%，用铟-111 巯基时为 82%，而使用含有肝素的血浆时，它们分别为 68%和仅 20%。向肝素化血浆中添加 ACD 消除了对更多配体的需求，并将 LE 提高到与仅含有 ACD 的血浆相同的值。这些结果清楚地表明，为了使用尽可能低浓度的托品酮或巯基获得高 LE，粒细胞必须在含有 ACD 的血浆中进行标记。
